Biology subjects

Connolly, N. M. C.

Publications and source records attributed to Connolly, N. M. C..

4 recordsLinked to original sources

bioRxiv2026

Spatiotemporal transcriptomics reveals distinct responses of ALDH1A1-positive and ALDH1A1-negative midbrain dopaminergic neurons to alpha-synuclein overexpression

Parkinsons disease is characterized by the progressive and preferential degeneration of dopaminergic neurons in the substantia nigra pars compacta, and intraneuronal alpha-synuclein (Syn) accumulation. Dopaminergic neurons (DANs) are anatomically and molecularly heterogeneous, but the impact of Syn pathology on distinct subpopulations is not well defined. One midbrain DAN sub-population expresses Aldehyde Dehydrogenase 1A1 (ALDH1A1), an enzyme that detoxifies aldehyde by-products of dopamine metabolism, and has been associated with differential vulnerability. Here, we applied GeoMx spatial transcriptomics to profile ALDH1A1-positive (ALDH1A1+) and ALDH1A1-negative (ALDH1A1-) DAN subpopulations in the mouse midbrain in situ at 3- and 8-weeks following adeno-associated virus (AAV)-mediated Syn overexpression. Analyzing 10,532 genes, we identified robust transcriptional differences between ALDH1A1+ and ALDH1A1- DANs under control conditions, supporting their characterization as distinct molecular subpopulations. In AAV-Syn-injected mice, we observed increased Snca expression and a reduction in ALDH1A1- DANs in the ipsilateral substantia nigra. Syn overexpression induced subpopulation-specific and time-dependent transcriptional responses, with dysregulation in ALDH1A1- DANs characterized by early down-regulation of pathways related to synaptic function, neurotransmitter handling, and bioenergetics, including glycolysis. In contrast, ALDH1A1+ DANs displayed later up-regulation of genes enriched for Acetyl-CoA and cholesterol metabolism pathways, reflecting subpopulation-specific adaptations to Syn overexpression. Analysis of human single nucleus RNA-sequencing data revealed partial conservation of the metabolic dysregulation signature. Together, our findings show that murine midbrain ALDH1A1+ and ALDH1A1- DANs represent molecularly distinct subpopulations with divergent temporal responses to Syn overexpression, emphasizing the importance of cell-type and disease-stage context in studies of Parkinsons disease mechanisms.

neuroscience↗

bioRxiv2025

Integrating simulated and experimental data to identify mitochondrial bioenergetic defects in Parkinson's Disease models

Mitochondrial bioenergetics are vital for ATP production and are associated with several diseases, including Parkinsons Disease. Here, we simulated a computational model of mitochondrial ATP production to interrogate mitochondrial bioenergetics under physiological and pathophysiological conditions, and provide a data resource that can be used to interpret mitochondrial bioenergetics experiments. We first characterised the impact of several common respiratory chain impairments on experimentally-observable bioenergetic parameters. We then established an analysis pipeline to integrate simulations with experimental data and predict the molecular defects underlying experimental bioenergetic phenotypes. We applied the pipeline to data from Parkinsons Disease models. We verified that the impaired bioenergetic profile previously measured in Parkin knockout neurons can be explained by increased mitochondrial uncoupling. We then generated primary cortical neurons from a Pink1 KO mouse model of Parkinsons, and measured reduced OCR capacity and increased resistance to Complex III inhibition. Here, our pipeline predicted that multiple respiratory chain impairments are required to explain this bioenergetic phenotype. Finally, we provide all simulated data as a user-friendly resource that can be used to interpret mitochondrial bioenergetics experiments, predict underlying molecular defects, and inform experimental design. HighlightsO_LIThe complexity of mitochondrial bioenergetics can make experimental data difficult to interpret. C_LIO_LIWe simulated a computational model of mitochondrial bioenergetics in healthy and pathological conditions, and established an analysis pipeline to integrate model simulations with experimental data. C_LIO_LIWe applied the pipeline to data from Parkinsons Disease models to predict the molecular defects underlying Parkinsons-related pathology. C_LIO_LIWe provide all outputs in a user-friendly Excel file, which serves as a valuable resource to the community for insight into the effects of pathology on mitochondrial bioenergetics and for interpretation of experimental results. C_LI

neuroscience↗

bioRxiv2022

MicroRNA-335-5p suppresses voltage-gated sodium channel expression and may be a target for seizure control

There remains an urgent need for new therapies for drug-resistant epilepsy (DRE). Sodium channel blockers are effective for seizure control in common forms of epilepsy, but loss of sodium channel function underlies some genetic forms of epilepsy. Approaches that provide bi-directional control of sodium channel expression are needed. MicroRNAs (miRNA) are small non-coding RNAs which negatively regulate gene expression. Here, we show that genome-wide miRNA screening of hippocampal tissue from a rat epilepsy model, mice treated with the novel anti-seizure medicine cannabidiol (CBD) and plasma from patients with DRE, converge on a single target, miR-335-5p. Pathway analysis on predicted and validated miR-335-5p targets identified multiple voltage-gated sodium channels (VGSCs). Intracerebroventricular injection of antisense oligonucleotides against miR-335-5p resulted in upregulation of Scn1a, Scn2a and Scn3a in the mouse brain and an increased action potential rising phase and greater excitability of hippocampal pyramidal neurons in brain slice recordings, consistent with VGSCs as functional targets of miR-335-5p. Blocking of miR-335-5p also increased voltage-gated sodium currents in human iPSC-derived neurons. Inhibition of miR-335-5p increased susceptibility to tonic-clonic seizures in the pentylenetetrazole seizure model, whereas AAV9-mediated overexpression of miR-335-5p reduced seizure severity and improved survival. These studies suggest modulation of miR-335-5p may be a means to regulate VGSCs and affect brain excitability and seizures. Changes to miR-335-5p may reflect compensatory mechanisms to control excitability and could provide new biomarker or therapeutic strategies for different types of drug-resistant epilepsy. Significance StatementDespite the clinical availability of over 30 anti-seizure medications (ASMs), around 30% of people with epilepsy do not achieve seizure freedom. MicroRNAs are small non-coding RNAs which negatively regulate protein expression by binding to target mRNAs. Here, we identified the brain-enriched miR-335-5p to be commonly altered in three heterogenous miRNA profiling datasets. Bi-directional modulation of miR-335-5p identified a potential homeostatic role of miR-335-5p in brain excitability involving voltage-gated sodium channels. Electrophysiological and in vivo approaches revealed pro-epileptic activity of miR-335-5p inhibition whereas overexpression of miR-335-5p resulted in anti-epileptic activity. Overall, targeting miR-335-5p could provide a new approach in the modulation of brain excitability, with possible therapeutic applications in drug-resistant epilepsies and other neurological diseases.

neuroscience↗

bioRxiv2019

Potent and lasting seizure suppression by systemic delivery of antagomirs targeting miR-134 timed with blood-brain barrier disruption

RNA therapies such as oligonucleotides (OGNs) offer precision treatments for a variety of neurological diseases, including epilepsy but their deployment is hampered by the blood brain barrier (BBB). Here we used brain imaging and assays of serum proteins and tracer extravasation, to determine that BBB disruption occurring after status epilepticus in mice was sufficient to permit passage of systemically-injected antisense OGNs targeting microRNA-134 (Ant-134) into the brain parenchyma. A single intraperitoneal injection of Ant-134 two hours after status epilepticus in mice resulted in potent suppression of spontaneous recurrent seizures, reaching a 99.5% reduction during recordings at three months. The duration of spontaneous seizures, when they occurred, was also reduced in Ant-134-treated mice. These studies indicate that systemic delivery of Ant-134 reaches the brain and produces disease-modifying effects after systemic injection in mice when timed with BBB disruption and may be a clinically-viable approach for this and other disease-modifying microRNA therapies.

neuroscience↗